Abel Hall LLC Purchases Shares of 4,993 Hims & Hers Health, Inc. $HIMS

Key Points

• Abel Hall LLC has acquired a new stake in Hims & Hers Health, purchasing 4,993 shares valued at approximately $249,000 during the second quarter.
• Hims & Hers Health's latest earnings report revealed a net margin of 9.63% and revenue of $544.83 million, which was below the consensus estimate of $550.06 million.
• Stock ratings from analysts vary, with two offering a Buy rating, nine maintaining a Hold, and three giving a Sell rating, resulting in an average consensus price target of $38.92.

Abel Hall LLC purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 4,993 shares of the company's stock, valued at approximately $249,000.

Other hedge funds also recently made changes to their positions in the company. Signaturefd LLC raised its stake in shares of Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock valued at $76,000 after purchasing an additional 388 shares during the period. Lake Hills Wealth Management LLC purchased a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $277,000. Occidental Asset Management LLC purchased a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $305,000. Dakota Wealth Management purchased a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $354,000. Finally, Fiduciary Alliance LLC raised its stake in shares of Hims & Hers Health by 120.4% during the second quarter. Fiduciary Alliance LLC now owns 109,253 shares of the company's stock valued at $5,446,000 after purchasing an additional 59,686 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HIMS. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Morgan Stanley restated an "equal weight" rating and issued a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Canaccord Genuity Group restated a "buy" rating and issued a $68.00 price target on shares of Hims & Hers Health in a research note on Friday, September 12th. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Finally, Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Stock Up 0.3%

HIMS stock opened at $58.12 on Thursday. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. Hims & Hers Health, Inc. has a 1-year low of $17.36 and a 1-year high of $72.98. The firm has a fifty day moving average price of $51.19 and a two-hundred day moving average price of $47.64. The firm has a market cap of $13.14 billion, a price-to-earnings ratio of 72.65, a PEG ratio of 3.92 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same quarter in the previous year, the firm earned $0.06 EPS. The firm's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 2,637 shares of the business's stock in a transaction on Monday, September 29th. The shares were sold at an average price of $58.79, for a total transaction of $155,029.23. Following the completion of the sale, the insider owned 163,767 shares in the company, valued at $9,627,861.93. The trade was a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Oluyemi Okupe sold 11,595 shares of the company's stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $57.72, for a total transaction of $669,263.40. Following the transaction, the chief financial officer owned 70,232 shares of the company's stock, valued at $4,053,791.04. This represents a 14.17% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,622,741 shares of company stock valued at $83,695,469 over the last quarter. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.